<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381627</url>
  </required_header>
  <id_info>
    <org_study_id>11021</org_study_id>
    <nct_id>NCT01381627</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Dexmedetomidine for EBUS-TBNA</brief_title>
  <acronym>EBUSed</acronym>
  <official_title>Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is the second most commonly diagnosed primary neoplasia in Canada accounting for
      22 865 new cases in 2007. Recent randomized trials have shown a significantly better
      diagnostic yield and fewer unnecessary thoracotomies with endobronchial ultrasound-guided
      transbronchial needle aspiration (EBUS-TBNA) when compared to conventional TBNA for various
      clinical conditions including peripheral pulmonary lesions and sarcoidosis. EBUS-TBNA are now
      routinely performed in our institution for staging of pulmonary and mediastinal cancer.
      EBUS-TBNA are performed under monitored anesthesia care (MAC) in the endoscopy suite at the
      Centre de soins ambulatoires of the Hôpital Maisonneuve-Rosemont.

      Remifentanil, used in combined regime or as single agent proved to be effective and safe for
      MAC. Nonetheless, anesthesiologists are still confronted to the respiratory depression
      profile of remifentanil and other commonly used agents. An analysis of the ASA Closed Claims
      demonstrated that respiratory depression remains a significant drawback during MAC in remote
      locations. Furthermore, patients with coexisting pulmonary diseases scheduled for EBUS-TBNA
      are at increased risk of such complications.

      The investigators hypothesize that compared to the use of remifentanil-based MAC protocol,
      the use of dexmedetomidine-based MAC protocol for EBUS-TBNA will result in a lower incidence
      of major respiratory and hemodynamic adverse events (bradypnea, apnea, oxygen desaturation,
      hypotension, hypertension, bradycardia and tachycardia) with equivalent overall procedure
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Bradypnea,apnea, oxygen desaturation, hypotension, hypertension, heart rate &lt;45 beats per minute, heart rate ≥120 beats per minute</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vocal cord movement</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Vocal cord movement before fiberscope passage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation scores</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Observer's Assessment of Alertness/Sedation Scale (OAA/S) throughout the EBUS-TBNA procedure. Specific time points: before fiberscope nasal insertion, before vocal cord passage, after vocal cord passage and at the end of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldrete scores in the post anesthesia care unit</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Aldrete score immediately after removal of fiberscope, time for Aldrete score equal or superior to 9 (assesed at 5 minute intervals).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of remifentanil or dexmedetomidine</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of lidocaine</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Cumulative dose of lidocaine administered by the endoscopist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of vasopressor</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Cumulative dose of vasopressor administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coughing episodes</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Coughing episodes throughout the EBUS-TBNA procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopist satisfaction</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Endoscopist global satisfaction score based on a 4-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Recall evaluation once Aldrete score superior to 9 in post anesthesia care unit. Evaluation based on a 4-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain associated with the procedure (VAS)</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Maximal pain evaluation based on a visual analog scale. Score measured once an Aldrete score superior to 9 in the post anesthesia care unit is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Patient followed for the entire duration of EBUS-TBNA (avg. 40 min) and until discharge of PACU (1 day total, ambulatory basis)</time_frame>
    <description>Global patient satisfaction associated with the procedure. Score based on a 5 point Likert scale. Measured before patient leaves the post anesthesia care unit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.</description>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with planned EBUS-TBNA under conscious sedation.

          -  Age 18-75 years old.

          -  American Society of Anesthesiologists class I-III.

          -  The subject is able to understand the study objectives, the experimental protocol and
             procedures, and is capable of providing an informed consent.

        Exclusion Criteria:

          -  Subjects allergic to any of the study drugs.

          -  BMI &gt; 34 kg/m2.

          -  Severe renal or hepatic failure.

          -  Pregnancy.

          -  Emergent procedure.

          -  Heart failure NYHA &gt; III.

          -  Systolic blood pressure &lt; 90 mmHg.

          -  Advanced heart block (unless patient has a pacemaker).

          -  Unstable angina and/or myocardial infarction within past 6 weeks.

          -  FEV1 ≤ 0.8 L.

          -  Oxygen-dependent patient.

          -  Use of α2-adrenoreceptor agonist or antagonist within 14 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Verdonck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Verdonck, MD</last_name>
    <phone>1-514-252-3426</phone>
    <email>overdonck@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia Godin, RN</last_name>
    <phone>1-514-252-3400</phone>
    <phone_ext>3193</phone_ext>
    <email>ngodin.hmr@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Louis-Philippe Fortier</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>EBUS-TBNA</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Precedex</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Ultiva</keyword>
  <keyword>Monitored Anesthesia Care</keyword>
  <keyword>Sedation</keyword>
  <keyword>Bronchoscopy</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Mediastinal node</keyword>
  <keyword>Cancer staging</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Remote location</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

